Efficacy of Protopic continues to improve over time2-4
- Maximal improvement was maintained with prolonged intermittent treatment3
- Significant continued improvement is seen with extended Protopic monotherapy3,8
- 81% and 86% of patients at month 6 and month 12, respectively, had marked or excellent improvement3
- No evidence of "rebound flare" was seen after extended therapy8
References
1. Data on file. Fujisawa Healthcare, Inc., Deerfield, Ill.
2. Hanifin JM, et al. J Am Acad Dermatol. 2001;44(suppl):S28-S38.
3. Reitamo S, et al. Arch Dermatol. 2000;136:999-1006.
4. Protopic® (tacrolimus) Ointment full prescribing information. Deerfield, Ill: Fujisawa Healthcare, Inc.; 2000.
5. Paller A, et al. J Am Acad Dermatol. 2001;44(suppl):S47-S57.
6. Leung D, et al. Proceedings of American Academy of Dermatology. February 2002; New Orleans, La.
7. Hanifin JM, et al. Exp Dermatol. 2001;10:11-18.
8. Kang S, et al. J Am Acad Dermatol. 2001;44(suppl):S58-S64.
Important Information
For short-term and intermittent long-term therapy in patients with moderate to severe atopic dermatitis who should avoid the potential risks of conventional therapies or are not adequately responsive to conventional therapies. Both 0.03% and 0.1% ointment can be used for adults. In children aged 2 to 15 years, only Protopic 0.03% is indicated.
The most common adverse events associated with the use of Protopic Ointment included the sensation of skin burning, pruritus, flu-like symptoms, and headache, and it is contraindicated in patients who are hypersensitive to tacrolimus or any of the other ingredients of Protopic.
Protopic Ointment should not be used with occlusive dressings.
Skin infections should be cleared prior to application, and there may be an increased risk of certain skin infections. Patients should minimize or avoid natural or artificial sunlight exposure.